Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Large Growth in Short Interest

Posted by ABMN Staff on Dec 30th, 2024

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 832,200 shares, an increase of 51.5% from the November 30th total of 549,400 shares. Based on an average daily trading volume, of 78,700 shares, the days-to-cover ratio is currently 10.6 days. Currently, 3.8% of the company’s shares are short sold.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GYRE. Charles Schwab Investment Management Inc. increased its holdings in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares during the period. Geode Capital Management LLC lifted its holdings in Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after buying an additional 43,840 shares during the period. Advantage Alpha Capital Partners LP bought a new stake in shares of Gyre Therapeutics in the 3rd quarter worth approximately $334,000. WINTON GROUP Ltd bought a new position in shares of Gyre Therapeutics during the second quarter valued at approximately $220,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Gyre Therapeutics during the second quarter valued at approximately $218,000. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Trading Down 5.2 %

NASDAQ:GYRE opened at $12.45 on Monday. The company has a fifty day moving average of $12.71 and a 200 day moving average of $12.66. Gyre Therapeutics has a 52 week low of $8.26 and a 52 week high of $27.45.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.